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People with Down syndrome (DS) have a neurodevelopmentally distinct brain and invariably developed
amyloid neuropathology by age 50. This cross-sectional study aimed to provide a detailed account of DS
brain morphology and the changes occuring with amyloid neuropathology. Forty-six adults with DS
underwent structural and amyloid imagingdthe latter using Pittsburgh compound B (PIB) to stratify the
cohort into PIB-positive (n ¼ 19) and PIB-negative (n ¼ 27). Age-matched controls (n ¼ 30) underwent
structural imaging. Group differences in deep gray matter volumetry and cortical thickness were studied.
PIB-negative people with DS have neurodevelopmentally atypical brain, characterized by dispropor-
tionately thicker frontal and occipitoparietal cortex and thinner motor cortex and temporal pole with
larger putamina and smaller hippocampi than controls. In the presence of amyloid neuropathology, the
DS brains demonstrated a strikingly similar pattern of posterior dominant cortical thinning and
subcortical atrophy in the hippocampus, thalamus, and striatum, to that observed in non-DS Alzheimer’s
disease. Care must be taken to avoid underestimating amyloid-associated morphologic changes in DS
due to disproportionate size of some subcortical structures and thickness of the cortex.
 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
People with Down syndrome (DS) are known to have develop-
mentally altered brain structure caused by trisomy of chromosome
21. Childrenwith DS present with delayed maturation of the central
nervous system, which has been linked to prenatal arrest of neuro-
genesis and synaptogenesis (Schmidt-Sidor et al., 1990; Wisniewski,
1990). Postmortem studies in adults with DS have found several
brain abnormalities, including reduced gross brain weight, a lower
number and depth of cerebral sulci, enlarged ventricles and hypo-
plasia of several brain structures such as the brainstem, cerebellum,
frontal and temporal lobes. In contrast, subcortical structures areand Developmental Disabil-
ersity of Cambridge, Douglas
. Tel.: þ44 1223 746127; fax:
Inc. This is an open access articleshown to be relatively preserved (de La Monte and Hedley-Whyte,
1990; Delabar et al., 2006; Dierssen, 2012; Dierssen and Ramakers,
2006; Lott and Dierssen, 2010). Imaging studies in adults with DS
have corroborated the postmortem ﬁndings by showingwidespread
cerebral hypoplasia and ventricular enlargement in comparison to
typically developing individuals (Supplementary Table 1, Aylward
et al., 1997a,b 1999; Beacher et al., 2009, 2010; Frangou et al., 1997;
Kesslak et al., 1994; Koran et al., 2014; Krasuski et al., 2002;
Pearlson et al., 1998; Pinter et al., 2001; Prasher et al., 2003; Raz
et al., 1995; Roth et al., 1996; Teipel et al., 2003, 2004; White et al.,
2003). The vast majority of neuroimaging studies, however, are
based on region-of-interest volumetry, which is only able to detect
volumetric changes in predetermined regions. There is a need to
study the structural morphology of the whole DS brain in a more
unbiased way.
In addition to the developmental abnormalities, people with DS
are at high risk for early-onset Alzheimer’s disease (AD) and have
been found to deposit b-amyloid plaques from about 40 years of ageunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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signiﬁcant amyloid binding with positron emission tomography
(PET) is found before any signs of cognitive or functional decline in
DS (Annus et al., 2016; Handen et al., 2012; Hartley et al., 2014;
Landt et al., 2011). Yet, previous structural imaging studies (see
Supplementary Table 1) have aimed to characterize the develop-
mental alterations of the adult DS brain by studying non-demented
individuals; such studies are, therefore, potentially confounded
through the aggregation of amyloid-positive and -negative partic-
ipants. For instance, 4 previous neuroimaging studies (Aylward
et al., 1999; Beacher et al., 2009; Pearlson et al., 1998; Prasher
et al., 2003) aimed to characterize cerebral atrophy associated
with AD in DS by comparing cognitively stable individuals to those
with a clinical diagnosis of dementia. It is highly likely, however,
that a sizable proportion of cognitively stable individuals already
had amyloidosis, and it is known from the general population
(Desikan et al., 2010; Dickerson and Wolk, 2011; Dickerson et al.,
2009) that abnormalities in cortical structure occur at presymp-
tomatic stages of AD. As such, the present cross-sectional study
aimed to characterize the morphology of the adult DS brain in the
absence of amyloid deposits and to describe the changes seen in the
presence of ﬁbrillar b-amyloid neuropathology.
2. Materials and methods
2.1. Study design and participants
Forty-six adults with DS and 30 typically developing partici-
pants (controls) took part in the present study. The DS cohort is the
same as that reported in a previous amyloid PET study (Annus et al.,
2016) with the exception of 2 amyloid-negative and 1 amyloid-
positive participant, whose magnetic resonance imaging (MRI)
scans were of inferior quality (motion artifact evident on visual
inspection) and hence unsuitable for reliable morphometric anal-
ysis. Adults with DS were identiﬁed via clinical and social services
for people with intellectual disabilities in England and Scotland and
via the DS Association (UK), whereas volunteers with typical neu-
rodevelopment were recruited from the local community via
advertisement. Control participants were screened to exclude
neurological and major psychiatric illness and developmental dis-
orders. All study participants were screened for contraindications
to MRI. Written consent was obtained from typically developing
controls and all adults with DS with capacity to consent. Verbal
assent was obtained from participants with DS lacking capacity, and
a written assent was provided by an appointed consultee, in
accordance with the UK Mental Capacity Act (2005). Ethics and
research and development approvals were granted by the National
Research Ethics Committee of East of EnglandeNorfolk and Cam-
bridgeshire and Peterborough NHS Foundation Trust, respectively.
2.2. Clinical assessments
All participants with DS had previously received a clinical
diagnosis of DS based on the characteristic phenotype with full
trisomy 21 conﬁrmed in 33 DS participants by karyotyping. All
participants with DS were assessed for dementia using the Cam-
bridge Examination for Mental Disorders in Older people with DS
and Others with Intellectual Disabilities informant interview as
described previously (Annus et al., 2016) and allocated into cate-
gories of “stable cognition”, “cognitive decline”, and “dementia”.
Dementia was diagnosed in accordance with the International
Classiﬁcation of Diseases-10 criteria and diagnosis of “cognitive
decline” was given to participants with evidence of functional
decline in one or more cognitive domains, whereas insufﬁcient to
satisfy the full criteria for dementia. All DS participants, except 3who had severe dementia and were untestable, were administered
the cognitive function assessmenteCAMCOGepart of the Cam-
bridge Examination for Mental Disorders in Older people with DS
and others with Intellectual Disabilities. With the exception of 1
demented individual who was receiving Donepezil, no participants
were using antidementia medications.
2.3. Magnetic resonance imaging acquisition
All participants underwent an anatomical MRI scan on
a Siemens Verio 3T scanner with 12-channel head coil (Siemens AG,
Erlangen, Germany) using the 3D T1-weighted magnet-
izationeprepared, rapid gradient echo pulse sequence with
the following parameters: repetition time/echo time/inversion
time/ﬂip angle ¼ 2300 ms/2.98 ms/900 ms/9, 256  240  176
matrix dimensions and 1  1  1 mm3 voxel size. Receiver
bandwidth and echo spacing were 240 Hz/pixel and 7.1 ms,
respectively, and parallel acceleration was disabled. The imaging
protocol included whole-brain, T2-weighted, half-Fourier acquisi-
tion, single-shot turbo spin echo sequence (repetition time/echo
time/ﬂip angle/turbo factor¼ 1500ms/79ms/150/256; 0.9 0.7
4.0 mm3 voxel size) to assess for vascular pathology and incidental
lesions. For all acquisitions, the ﬁeld of view was aligned in ste-
reotactic space, with the axial plane aligned to the anterior com-
missureeposterior commissure line and the sagittal plane to the
interhemispheric ﬁssure.
2.4. Positron emission tomography using [11C]ePittsburgh
compound B
Details of the PIB PET data acquisition and processing have been
published previously (Annus et al., 2016). Brieﬂy, PIB PET images
were acquired in 3D mode on a GE Advance scanner (General
Electric Medical Systems, Milwaukee,WI, USA) for 90minutes post-
PIB injection in 58 frames. Only participants with DS were assessed
for amyloid. Cortical regional PIB analysis was based on Brodmann
areas, whereas subcortical regions of interest were based on deep
gray matter parcelations using FIRST (Patenaude et al., 2011) and
included the striatum (caudate nucleus and putamen), amygdala,
thalamus, and hippocampus. For each region of interest, non-
displaceable binding potential was obtained using a basis function
implementation of the simpliﬁed reference tissue model (Gunn
et al., 1997) with superior cerebellar gray matter as reference re-
gion. PIB-positive and PIB-negative groups were assigned on the
basis of striatal nondisplaceable binding potential, which had pre-
viously revealed a bimodal distribution with clear separation of
positive and negative groups (Annus et al., 2016). Of the 46 par-
ticipants with DS, 19 were PIB-positive.
2.5. Image processing
2.5.1. Cortical thickness analysis
Cortical thickness analysis was conducted using FreeSurfer
(v5.3, available from https://surfer.nmr.mgh.harvard.edu). The
detailed procedure for surface reconstruction and estimation of
cortical thickness has been described previously (Dale et al., 1999;
Fischl and Dale, 2000; Fischl et al., 1999). Image processing
involved automated nonuniformity bias correction, skull stripping,
segmentation of the white matter, and estimation of the gray/white
matter boundary. Segmented and skull-stripped data of all partic-
ipants were visually inspected for parcelation errors, and topolog-
ical defects in the gray/white matter boundary were manually
corrected. The gray/white boundary served as a starting point for a
deformable surface algorithm to compute the gray/white and pial
surfaces, from which cortical thickness is calculated as the closest
T. Annus et al. / Neurobiology of Aging 53 (2017) 11e19 13distance from the gray/white matter boundary to the pial surface at
each vertex on the tessellated surface. Thickness measurements
were mapped on the inﬂated surface of each participant’s brain
reconstruction for visualization of data across the entire cortical
surface. The thickness measurements using this technique have
been shown to be both valid (Rosas et al., 2002) and reliable
(Dickerson et al., 2008). Each participant’s brainwas then morphed
and aligned to a spherical common surface template using a high-
resolution surface-based averaging technique that aligns cortical
folding patterns by individual sulci and gyri. Before analysis, the
data were smoothed with a 25 mm full-width at half-maximum
Gaussian kernel, the rationale for using a large kernel size has
been published previously (Diaz-de-Grenu et al., 2014). Statistical
analysis was performed using the QDEC module implemented in
FreeSurfer. For each hemisphere, General Linear Model was applied
to estimate variations in cortical thickness at each vertex of the
surface. Statistical surface maps were created using a vertexwise
statistical threshold of p < 0.05 corrected for false discovery rate at
q < 0.05. Covariate of interest analysis in FreeSurfer demonstrated
no signiﬁcant gender or total intracranial volume (TIV) speciﬁc
regional differences in cortical thickness between PIB-negative
group and neurotypical controls, resulting in the exclusion of
both covariates from the statistical models (data not shown).
Furthermore, b-amyloid has been shown to be a function of age in
people with DS (Annus et al., 2016) and by controlling for age, the
true effects of AD would be removed. A subgroup analysis was
conducted in age-matched PIB-negative and PIB-positive group by
including all individuals, who were in the age bracket of
39e48 years representing the time from ﬁrst evidence of amyloid
binding to the whole cohort being positive on PIB PET (for detailed
results, see Annus et al., 2016).
2.5.2. Deep gray matter volumetry
Deep brain regions of interest were deﬁned by constructing a
mask of these structures using FIRST (Patenaude et al., 2011, avail-
able from: http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FIRST). Individual
structural neuroimaging data were registered by a 2-stage afﬁne
transformation to a standard Montreal Neurological Institute space
with 1mm3 resolution using 12 degrees of freedom, after which the
registered data was ﬁtted with “a surface mesh” modeled using a
multivariate Gaussian model based on the shape and intensity in-
formation from the normalized T1-images (Patenaude et al., 2011).
The segmentationwas performed on all subcortical structures using
the run_ﬁrst_all wrapper with default settings and visually
inspected for errors and misregistrations. As a result, nucleus
accumbens, brainstem, and globus pallidus were excluded from theTable 1
Participant demographics
Measure Controls PIB-negati
n, f/m 30, 14/16 27, 13/14
Age, range (y) 46.2  9.7, 30e64 37.1  6, 2
Global cortical thickness (mm) 2.57  0.09 2.68  0.1
TIV (cm3) 1421.71  140.58 1178.71 
TIV-corrected TBVa (cm3) 1151.26  59.52 1148.86 
Stable cogn./cogn. decline/dement. N/A 24/1/2
CAMCOG score (max 109), range N/A 76, 38e10
ApoEb
ε2/ε3 N/A 4
ε3/ε3 N/A 15
ε3/ε4 N/A 4
ε2/ε4 N/A 1
Data is shown as mean  standard deviation and range, if applicable.
Key: ApoE, apolipoprotein E allele; Cogn. decline, cognitive decline; Dement., dementia; f
brain volume; TIV, total intracranial volume.
a Jack et al. (1989).
b Three individuals in the PIB-negative group and 3 in the PIB-positive group did notanalyses due to their small size, poor segmentation, and high fre-
quency of calciﬁed lesions, respectively. Volumes of the structures
of interest (putamen, caudate nucleus, thalamus, hippocampus, and
amygdala) for each hemisphere were calculated and corrected for
TIV (Jack et al., 1989). To limit the number of statistical tests, vol-
umes of the left and right hemisphere structures were averaged for
group comparisons. TIV and total brain volumes were determined
by summing the relevant tissue classes using Statistical Parametric
Mapping (Pengas et al., 2009). All calculated volumes were nor-
mally distributed across study groups (Shapiro-Wilk test, all p >
0.05), thus parametric tests in SPSS Statistics 22.0 (IBM, Corp) were
implemented for statistical analyses. Between-group differences
were assessed using 1-way analysis of variance, whereas inde-
pendent group and correlation analyses were conducted using in-
dependent sample t-test (all 2-tailed) and Pearson’s correlation
test, respectively. The relationship between categorical variables
was assessed using chi-squared test. A signiﬁcance level of p < 0.05
was used for all inferences with results reported as mean and
standard deviation.
3. Results
3.1. Demographics and summary measures
Participant demographics are provided in Table 1. Participants in
the PIB-negative group were signiﬁcantly younger than controls
[t(48) ¼ 4.311, p < 0.001] and the PIB-positive group
[t(37)¼6.722, p< 0.001],whereas controls and PIB-positive group
were of similar ages [t(47)¼ 1.491, p¼ 0.143]. The control group had
signiﬁcantly larger TIV than PIB-negative [t(55) ¼ 7.370, p < 0.001]
and PIB-positive [t(47) ¼ 5.535, p < 0.001] individuals with DS,
whereas there was no difference in TIV between the 2 DS groups
[t(44) ¼ 0.735, p ¼ 0.466]. The PIB-positive group had signiﬁcantly
lower TIV-corrected total brain volume than PIB-negative group
[t(44) ¼ 5.304, p < 0.001], as well as controls [t(47) ¼ 4.444,
p < 0.001]. PIB-negative and control groups had similar TIV-
corrected total brain volume [t(55) ¼ 0.189, p ¼ 0.850]. Further-
more, on average, the isocortex in the PIB-negative group was 4.3%
thicker than that in controls and 4.9% thicker than that in the PIB-
positive group, whereas PIB-positive and control group had similar
mean global cortical thickness (0.56% lower in PIB-positive,
Supplementary Fig. 1). No differences were observed in the cogni-
tive function test CAMCOG between PIB-negative and PIB-positive
groups [t(41) ¼ 1.057, p ¼ 0.297]. Note, however, that 3 in-
dividuals in the PIB-positive group were untestable because of
dementiadfor this reason, analyses were also run excluding these 3ve PIB-positive PIB-positive excl. 3 non-CAMCOG
participants
19, 8/11 16, 6/10
8e48 49.7  6.5, 39e65 48.1  5.1, 39e56
0 2.55  0.12 2.56  0.12
103.13 1203.40  124.10 1203.03  115.00
29.87 1067.08  72.05 1070.26  73.94
7/5/7 7/5/4
2 - 74, 17e95
3 2
6 6
6 6
1 1
/m, females/males ratio; N/A, not applicable; Stable cogn., stable cognition; TBV, total
undergo ApoE genotyping.
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matched for CAMCOG performance. Excluding these 3 severely
demented individuals did not inﬂuence theﬁndings reported for the
overall PIB-positive group (Table 1). Interestingly, even the cogni-
tively stable participants in the PIB-positive group had signiﬁcantly
lower TIV-corrected total brain volume [1087.98  72.82 cm3 vs.
1148.05  31.27 cm3, respectively; t(29) ¼ 3.232, p ¼ 0.003] and
lower mean global cortical thickness [2.58  0.10 mm vs. 2.68 
0.10 mm, respectively; t(29) ¼ 2.425, p ¼ 0.022] than cognitively
stable participants in the PIB-negative group.3.2. Cortical thickness
3.2.1. PIB-negative Down syndrome versus controls
The vertexwise analysis in the PIB-negative group compared
with controls demonstrated highly signiﬁcant cortical thinning in
the precentral gyrus; signiﬁcant thinning was also found in the
temporal pole with additional small areas in subgenual anterior
cingulate and retrosplenial cortex (Fig. 1). Widespread cortical
thickness increases relative to controls were evident in medial and
lateral prefrontal cortex; parietal, precuneus, and posterior cingu-
late cortex; postcentral gyrus; occipital and posteroinferior
temporal cortex. Controlling for age differences between PIB-
negative and control group did not alter the main ﬁndings (see
Supplementary Fig. 2).
3.2.2. PIB-positive Down syndrome versus PIB-negative Down
syndrome
Vertexwise analysis of cortical thickness in the PIB-positive
compared to PIB-negative group revealed large conﬂuent clusters
of cortical thinning in parieto-temporo-occipital cortices, posterior
cingulate, and precuneus cortices along with some small and
scattered changes in prefrontal areas. The extent of cortical thinning
was more marked in the right hemisphere. In contrast, there were
some small, weakly signiﬁcant areas of greater thickness in the PIB-
positive group in the right subgenual cortex and left precentral
gyrus (Fig. 2). Removal of the 3 PIB-positive DS individuals, who
were too advanced to complete the CAMCOG, did not alter the re-
ported ﬁndings (data not shown). Although PIB-negative groupwas
signiﬁcantly younger than PIB-positive, matching the groups for
age is problematic because, by deﬁnition, transition to amyloidFig. 1. The cortical signature of the Down syndrome brain without amyloid pathology: regi
(n ¼ 27) in comparison to control group (n ¼ 30). The color scale on the right represents the
thinner cortex and blue-light blue indicating thicker cortex in the PIB-negative group relatpositivity is a function of age in people with DS (see Annus et al.,
2016). Nonetheless, the age bracket from 39 to 48 years contained
an overlap of PIB-positive (n ¼ 9) and PIB-negative (n ¼ 13)
participants that were matched for age [t(20) ¼ 1.481, p ¼ 0.154].
Reducing the power by only looking at this subgroup meant
that the signiﬁcance of the changes diminished, however at p
(uncorr) < 0.05, a similar atrophy pattern to that seen in the full
cohort contrast was evident (Supplementary Fig. 3).3.3. Deep gray matter volumetry
Compared to controls, the PIB-negative group had signiﬁcantly
larger TIV-corrected putamina [t(55) ¼ 5.351, p < 0.001] and
smaller hippocampi [t(55) ¼ 4.951, p < 0.001], whereas no volu-
metric differences were identiﬁed in the caudate nucleus and
thalamus. The results remained unaltered, when corrected for
differences in age between the 2 groups (data not shown).
Relative to the PIB-negative group, the PIB-positive group demon-
strated signiﬁcantly atrophic caudate nucleus [t(44) ¼ 2.323, p <
0.05], putamen [t(44) ¼ 5.52, p < 0.001], thalamus [t(44) ¼ 3.277,
p ¼ 0.01], and hippocampus [t(44) ¼ 4.258, p < 0.001], whereas
only thalamic [t(47) ¼ 4.289, p < 0.001] and hippocampal volumes
[t(47) ¼ 8.361, p < 0.001] were smaller when compared to controls.
There were no signiﬁcant differences in the TIV-corrected volumes
of amygdala [F(3,75) ¼ 0.878, p ¼ 0.42] across the 3 groups (Fig. 3).
Furthermore, the inclusion of 3 severely demented individuals in
the PIB-positive group, who were untestable on the CAMCOG
assessment, had no impact on the deep gray matter volumetry
ﬁndings in the PIB-positive group (unﬁlled circles, Fig. 3).4. Discussion
The present study demonstrated a distinct neurodevelopmental
phenotype of the DS brainwith evidence of a thicker cortical ribbon
particularly in the frontal and occipital lobes and thinner motor
cortex. Development of ﬁbrillar b-amyloidosis in people with DS is
associated with a widespread posterior cortical thinning and
subcortical atrophy in a pattern highly concordant with that seen in
sporadic (Dickerson et al., 2009; Fjell et al., 2014; Jack et al., 2009)
and familial AD (Cash et al., 2013; Fortea et al., 2010). This study is
the ﬁrst of its kind to provide a comprehensive analysis of theonal variations in cortical thickness across the hemispheres in the PIB-negative group
signiﬁcance of the thickness difference as log 10 (p-value) with red-yellow indicating
ive to controls. The results are false discovery rate corrected at p < 0.05.
Fig. 2. The cortical signature of the Down syndrome brain with amyloid pathology: regional variations in cortical thickness in the PIB-positive group (n ¼ 19), when compared to
PIB-negative group (n ¼ 27). The color scale on the right represents the signiﬁcance of the difference in thickness as log 10 (p-value) with red-yellow indicating thinner cortex and
blue-light blue indicating thicker cortex in the PIB-positive group relative to PIB-negative group. The results are false discovery rate corrected at p < 0.05.
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clearly deﬁned according to amyloid status.4.1. The structure of the Down syndrome brain without amyloid
It is expected that the DS brain differs qualitatively from that of
the typically developing population. The aim of the contrast of
amyloid-negative DS to healthy controls was to map these differ-
ences and, therefore, to aid interpretation of the changes that then
occur in the DS brain in the presence of amyloid.With amean age of
46 years, it was considered highly unlikely that the control group
would be contaminated with amyloid-positive participants. In line
with previous work (see Supplementary Table 1), adults with DS
presented with signiﬁcantly lower TIV compared to neurotypical
controls. The current ﬁndings indicate, however, that the DS brain is
not simply a downscale model of the typically developed brain but
has a distinct topography of regions that are disproportionally
smaller or larger with respect to the smaller brain size. In the
absence of amyloid, the brain of people with DS is characterized by
atypically and disproportionally thicker cortex in the frontal, pari-
etal, occipitotemporal, and posterior cingulate areas. Furthermore,
people with DS have neurodevelopmentally thinner motor cortices
and temporal poles. The present ﬁndings are in line with a recent
report of increased cortical thickness in the frontal, parietal, and
occipital lobes in children and young adults with DS (mean age:
15 years, range: 5e24 years; Lee et al., 2016), demonstrating that a
largely thicker cortex is present already in childhood and persists
into adulthood in individuals with DS. However, the authors only
focused on the pattern of thicker cortex in the DS youth in com-
parison to typically developing youth and did not investigate the
reverse contrast, thus possibly missing the pattern of cortical
thinning described in the present study. Interestingly, the regions
that are atypically thicker in DS are characterized by pronounced
cortical thinning during brain development in adolescents without
trisomy 21 (Vandekar et al., 2015). This suggests a delay in the
cortical thinning in DS and that the abnormalities in the develop-
ment and maturation of the cortex extend beyond early develop-
ment well into adulthood.
In deep gray matter structures, the most striking differences
between people with DS and neurotypical controls was in thestriatumdspeciﬁcally that the putamen was disproportionately
enlarged in amyloid-negative adults with DS. Disproportionally
greater volume of the putamen has been previously found in a
morphometry study of children (Menghini et al., 2011) and in
nondemented adults with DS (Aylward et al., 1997b; Beacher et al.,
2010), when compared to typically developing individuals. This
again points to a neurodevelopmental origin of the observed
structural enlargement, in line with the ﬁndings of increased
cortical thickness as a result of abnormal cortical development and
maturation in DS.
The hippocampi were disproportionally smaller in PIB-negative
individuals with DS compared to neurotypical controlsda ﬁnding
consistent with previous in vivo volumetry reports (Kesslak et al.,
1994; Krasuski et al., 2002; Menghini et al., 2011; Raz et al., 1995;
Smigielska-Kuzia et al., 2011; White et al., 2003). As the present
study was cross-sectional, it cannot address whether this reduction
in hippocampal volume in adults with DS is developmental (hy-
poplasia) or acquired (atrophy). It would seem, however, to almost
certainly represent hypoplasia because past studies have found
decreased hippocampal volume in adults younger than 30 years
(Raz et al., 1995), as well as in adolescents (Menghini et al., 2011)
and children (Smigielska-Kuzia et al., 2011) with DS. Although these
past studies did not include amyloid imaging, it seems reasonable
to assume, based on amyloid PET (Annus et al., 2016) and pathology
(Mann and Esiri, 1989) studies, that such participants would have
been amyloid negative. The rest of the subcortical structures,
including the thalamus and the amygdala, did not exhibit any DS
speciﬁc characteristics in the absence of PIB binding and were
neurodevelopmentally proportional to those of typically devel-
oping controls.4.2. The PIB-positive Down syndrome brain
A signiﬁcant reduction in TIV-corrected total brain volume was
observed in the PIB-positive group, when compared to the PIB-
negative group. In addition to marked volumetric differences,
amyloid-positive individuals also presented with signiﬁcantly
lower mean global cortical thickness than their amyloid-negative
counterparts. This reduction in both volume and cortical thick-
ness was signiﬁcant even in the cognitively stable PIB-positive
Fig. 3. Volumesof thedeepgraymatter structures and total brain in the control, PIB-negativeandPIB-positive groups. Unﬁlled circles in thePIB-positive group represent the3 individuals
whohad tooadvanceddementia tobe able toperform theCAMCOGcognitiveassessment. *p< 0.05, ***p<0.001,NS, nonsigniﬁcant. All tests are 2-sample t-test results (2-tailed) following
a 1-way analysis of variance. Abbreviation: CAMCOG, Cambridge Examination for Mental Disorders in Older people with DS and others with Intellectual Disabilities.
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T. Annus et al. / Neurobiology of Aging 53 (2017) 11e19 17participants, demonstrating that, in keeping with sporadic
(Aizenstein et al., 2008; Becker et al., 2011) and familial AD (Klunk
et al., 2007; Villemagne et al., 2009), volume loss and cortical
thinning is measurable before any clinical signs of cognitive decline
in people with DS. The neocortex of PIB-positive adults with DS
exhibited a pattern of posterior dominant cortical thinning mapped
to the parietoetemporo-occipital cortices laterally and to the
medial posterior cingulate and precuneus cortices. This pattern of
reduced thickness in DS was highly similar to that observed in
sporadic and familial AD (Boxer et al., 2003; Cash et al., 2013; Du
et al., 2007; Fjell et al., 2014; Gili et al., 2011). The volumes of pu-
tamen and caudate were signiﬁcantly lower in PIB-positive in-
dividuals with DS compared to either the PIB-negative group or
typically developing controls. This result highlights the importance
of amyloid stratiﬁcation in DSethe striatal volume reduction would
be missed entirely if one examined volumetric changes in PIB-
positive DS only in comparison to a neurotypical control group.
The striatum has been receiving increasing interest in the ﬁeld of
AD, particularly as it has been shown to be the ﬁrst site of PET
amyloid binding in the familial forms of early onset AD (Klunk et al.,
2007; Koivunen et al., 2008; Pievani et al., 2013; Remes et al., 2008;
Villemagne et al., 2009) and recently in people with DS (Annus
et al., 2016; Handen et al., 2012).
The PIB-positive group demonstrated signiﬁcant reduction in
the thalamic volume, when compared to amyloid negative in-
dividuals. PIB positivity was also associated with marked hippo-
campal volume reduction, when contrasted to PIB-negative DS
group. As already noted, the TIVecorrected hippocampal volumes
in PIB-negative individuals with DS were, in turn, signiﬁcantly
smaller than controls. Hippocampal atrophy is an expected ﬁnding
in AD, although it is interesting to note that the effect size was
comparable to that for putaminal atrophy (Fig. 3) in the amyloid-
positive DS group. Given that many of the amyloid-positive in-
dividuals in the present series were asymptomatic, these ﬁndings
suggest that atrophy becomes measurable very early after the
conversion to amyloid positivity, although this hypothesis would
need to be proven in a longitudinal sample.
4.3. Limitations
The present study is the ﬁrst in characterizing the brain
morphology in neuropathologically clearly deﬁned groups of
amyloid-positive and -negative adults with DS. There were,
however, inevitable age differences between the PIB-negative and
PIB-positive group as a result of age-dependent threshold of
amyloidosis in the DS population (Annus et al., 2016). As such, it is
not possible to control for the differences in age in the statistical
models without removing the effects of amyloid. Although the lack
of age-matched groups is a limitation of the present study,
repeating the cortical thickness analysis in smaller (n¼ 22) but age-
matched groups of 39- to 48-year-olds yielded similar results
(Supplementary Fig. 3). Although the signiﬁcance (expectedly)
diminished, the results were consistent with the full group analysis
suggesting that they were not spurious and, in turn, making it very
unlikely that the whole group results were merely driven by
between-group age differences. Three individuals in the PIB-
negative group were diagnosed with dementia (n ¼ 2/3) or cogni-
tive decline (n ¼ 1/3) albeit having no evidence of amyloidosis in
PIB-PET. Diagnosing dementia in people with intellectual disabil-
ities (including DS) is a challenge with an acknowledged risk of
uncertainty, particularly exacerbated by the presence of underlying
intellectual disability, frequent lack of information about in-
dividual’s premorbid level of functioning and difﬁculties in
communication and therefore heavy reliance on informant opinion
(Burt et al., 1998; for discussion see Annus et al., 2016).Furthermore, changes associated with amyloid deposition in DS are
described using a cross-sectional dataset. Although longitudinal
studies are needed to understand better the relationship between
sub/cortical atrophy and amyloidosis, the present ﬁndings have
highlighted that, in the presence of conﬁrmed amyloidosis, the
pattern of cortical thinning is similar across AD regardless of eti-
ology. Finally, it will be of interest in future studies with greater
power to examine the severity of atrophy stratiﬁed not just for
amyloidosis but also with respect to clinical status (i.e., stable
cognition/cognitive decline/dementia); in the present cohort (see
Table 1) such a stratiﬁcation resulted in groups that were too small
to reliably address this issue.
5. Conclusion
This study is the ﬁrst to describe the cortical landscape of the
adult DS brain in distinct neuropathologically deﬁned groups.
Adults with DS presented with signiﬁcant neuroanatomical differ-
ences from typically developing controls, which were further
exacerbated in those individuals with evidence of amyloid pathol-
ogy on a PIB PET scan. In the absence of amyloid, peoplewith DS had
smaller brain volume but with atypically thicker cortex in the
frontal and occipitoparietal cortices and thinner motor cortex and
temporal pole compared to controls. The data also demonstrated
that, compared to the general population, people with DS had
disproportionately larger putamina and smaller hippocampi, likely
a result of abnormal brain development and maturation. In the
presence of amyloidosis, adults with DS demonstrated posterior
dominant cortical thinning as well as atrophy in the hippocampi,
thalami, and striatum in a strikingly similar pattern as observed in
sporadic and familiar AD. The data further showed that people with
DS can tolerate signiﬁcant cortical atrophy in the presence of am-
yloid without deleterious effects on their cognitive function. The
present study has highlighted the importance of ﬁrst understand-
ing the neuroanatomical characteristics of the DS brain before any
assessments of the effects of amyloid are undertaken. Thus, care
must be taken when characterizing amyloid-related structural
changes in individuals with DS to avoid underestimation of the
observed morphology due to disproportionate size of some deep
gray matter structures and increased thickness of the cortex.
Disclosure statement
The authors report no conﬂict of interest.
Acknowledgements
The research team would like to thank the PET imaging tech-
nologist, MRI radiographers, technicians, and radiochemists at the
Wolfson Brain Imaging Centre for their help in acquiring the neu-
roimaging data. The authors would also extend their sincere grat-
itude to all the participants with DS, their families and careers for
their time, commitment and support of the Dementia in Down
syndrome study conducted at the University of Cambridge. Finally,
the recruitment for this study was generously supported by the
Down Syndrome Association (UK) and the care organisation Hft.
The views expressed are those of authors and not necessarily those
of the Medical Research Council, the NIHR, or the Department of
Health.
This workwas supported by theMedical Research Council (grant
number: 98480). Additional support was received from the NIHR
Cambridge Biomedical Research Centre, the NIHR Collaborations in
Leadership for Applied Health Research and Care (CLAHRC) for the
East of England, the NIHR Cambridge Dementia Biomedical
T. Annus et al. / Neurobiology of Aging 53 (2017) 11e1918Research Unit, the Down Syndrome Association and the Health
Foundation.
The sponsors of the study had no role in the design and conduct
of the study; collection, management, analysis, and interpretation
of the data; writing and review of the report; and decision to
submit the article for publication.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.neurobiolaging.
2017.01.009.References
Aizenstein, H.J., Nebes, R.D., Saxton, J.A., Price, J.C., Mathis, C.A., Tsopelas, N.D.,
Ziolko, S.K., James, J.A., Snitz, B.E., Houck, P.R., Bi, W., Cohen, A.D., Lopresti, B.J.,
DeKosky, S.T., Halligan, E.M., Klunk, W.E., 2008. Frequent amyloid deposition
without signiﬁcant cognitive impairment among the elderly. Arch. Neurol. 65,
1509e1517.
Annus, T., Wilson, L.R., Hong, Y.T., AcostaeCabronero, J., Fryer, T.D.,
CardenaseBlanco, A., Smith, R., Boros, I., Coles, J.P., Aigbirhio, F.I., Menon, D.K.,
Zaman, S.H., Nestor, P.J., Holland, A.J., 2016. The pattern of amyloid accumulation
in the brains of adults with Down syndrome. Alzheimers Dement 12, 538e545.
Aylward, E.H., Habbak, R., Warren, A.C., Pulsider, M.B., Barta, P.E., Jerram, M.,
Pearlson, G.D., 1997a. Cerebellar volume in adults with Down syndrome. Arch.
Neurol. 54, 209e212.
Aylward, E.H., Li, Q.A., Habbak, R., Warren, A., Pulsifer, M.B., Barta, P.E., Jerram, M.,
Pearlson, G.D., 1997b. Basal ganglia volume in adults with Down syndrome.
Psychiatry Res. Neuroimaging 74, 73e82.
Aylward, E.H., Li, Q.A., Honeycutt, N.A., Warren, A.C., Pulsifer, M.B., Barta, P.E.,
Chan, M.D., Smith, P.D., Jerram, M., Pearlson, G.D., 1999. MRI volumes of the
hippocampus and amygdala in adults with Down’s syndrome with and without
dementia. Am. J. Psychiatry 156, 564e568.
Beacher, F., Daly, E., Simmons, A., Prasher, V., Morris, R., Robinson, C., Lovestone, S.,
Murphy, K., Murphy, D.G.M., 2009. Alzheimer’s disease and Down’s syndrome:
an in vivo MRI study. Psychol. Med. 39, 675e684.
Beacher, F., Daly, E., Simmons, A., Prasher, V., Morris, R., Robinson, C., Lovestone, S.,
Murphy, K., Murphy, D.G.M., 2010. Brain anatomy and ageing in non-demented
adults with Down’s syndrome: an in vivo MRI study. Psychol. Med. 40, 611e619.
Becker, J.A., Hedden, T., Carmasin, J., Maye, J., Rentz, D.M., Putcha, D., Fischl, B.,
Greve, D.N., Marshall, G.A., Salloway, S., Marks, D., Buckner, R.L., Sperling, R.A.,
Johnson, K.A., 2011. Amyloid-beta associated cortical thinning in clinically
normal elderly. Ann. Neurol. 69, 1032e1042.
Boxer, A., Rankin, K., Miller, B., Schuff, N., Weiner, M., Gorno-Tempini, M., 2003.
Cinguloparietal atrophy distinguishes Alzheimer disease from semantic de-
mentia. Arch. Neurol. 60, 949e956.
Burt, D.B., Loveland, K.A., Primeaux-Hart, S., Chen, Y.-W., Phillips, N.B.,
Cleveland, L.A., Lewis, K.R., Lesser, J., Cummings, E., 1998. Dementia in adults
with Down syndrome: diagnostic challenges. Am. J. Ment. Retard. 103, 130e145.
Cash, D.M., Ridgway, G.R., Liang, Y.Y., Ryan, N.S., Kinnunen, K.M., Yeatman, T.,
Malone, I.B., Benzinger, T.L.S., Jack, C.R., Thompson, P.M., Ghetti, B.F., Saykin, A.J.,
Masters, C.L., Ringman, J.M., Salloway, S.P., Schoﬁeld, P.R., Sperling, R.A.,
Cairns, N.J., Marcus, D.S., Xiong, C., Bateman, R.J., Morris, J.C., Rossor, M.N.,
Ourselin, S., Fox, N.C. DIAN, 2013. The pattern of atrophy in familial Alzheimer
disease volumetric MRI results from the DIAN study. Neurology 81, 1425e1433.
Dale, A.M., Fischl, B., Sereno, M.I., 1999. Cortical surface-based analysis: I. Seg-
mentation and surface reconstruction. Neuroimage 9, 179e194.
De La Monte, S.M., Hedley-Whyte, E.T., 1990. Small cerebral hemispheres in adults
with Down’s syndrome: contributions of developmental arrest and lesions of
Alzheimer’s disease. J. Neuropathol. Exp. Neurol. 49, 509e520.
Delabar, J.M., Aﬂalo-Rattenbac, R., Creau, N., 2006. Developmental defects in trisomy
21 and mouse models. Scientiﬁc World J. 6, 1945e1964.
Desikan, R.S., Sabuncu, M.R., Schmansky, N.J., Reuter, M., Cabral, H.J., Hess, C.P.,
Weiner, M.W., Bifﬁ, A., Anderson, C.D., Rosand, J., Salat, D.H., Kemper, T.L.,
Dale, A.M., Sperling, R.A., Fischl, B., 2010. Selective disruption of the cerebral
neocortex in Alzheimer’s disease. PLoS One 5, e12853.
Diaz-de-Grenu, L.Z., Acosta-Cabronero, J., Chong, Y.F., Pereira, J.M., Sajjadi, S.A.,
Williams, G.B., Nestor, P.J., 2014. A brief history of voxel-based grey matter
analysis in Alzheimer’s disease. J. Alzheimers Dis. 38, 647e659.
Dickerson, B.C., Bakkour, A., Salat, D.H., Feczko, E., Pacheco, J., Greve, D.N.,
Grodstein, F., Wright, C.I., Blacker, D., Rosas, H.D., Sperling, R.A., Atri, A.,
Growdon, J.H., Hyman, B.T., Morris, J.C., Fischl, B., Buckner, R.L., 2009. The
cortical signature of Alzheimer’s disease: regionally speciﬁc cortical thinning
relates to symptom severity in very mild to mild AD dementia and is detectable
in asymptomatic amyloid-positive individuals. Cereb. Cortex 19, 497e510.
Dickerson, B.C., Fenstermacher, E., Salat, D.H., Wolk, D.A., Maguire, R.P., Desikan, R.,
Pacheco, J., Quinn, B.T., Van der Kouwe, A., Greve, D.N., Blacker, D., Albert, M.S.,
Killiany, R.J., Fischl, B., 2008. Detection of cortical thickness correlates ofcognitive performance: reliability across MRI scan sessions, scanners, and ﬁeld
strengths. Neuroimage 39, 10e18.
Dickerson, B.C., Wolk, D.A., 2011. Dysexecutive versus amnesic phenotypes of very
mild Alzheimer’s disease are associated with distinct clinical, genetic and
cortical thinning characteristics. J. Neurol. Neurosurg. Psychiatry 82, 45e51.
Dierssen, M., 2012. Down syndrome: the brain in trisomic mode. Nat. Rev. Neurosci.
13, 844e858.
Dierssen, M., Ramakers, G.J.A., 2006. Dendritic pathology in mental retardation:
from molecular genetics to neurobiology. Genes Brain Behav. 5, 48e60.
Du, A.-T., Schuff, N., Kramer, J.H., Rosen, H.J., Gorno-Tempini, M.L., Rankin, K.,
Miller, B.L., Weiner, M.W., 2007. Different regional patterns of cortical thinning
in Alzheimer’s disease and frontotemporal dementia. Brain 130, 1159e1166.
Fischl, B., Dale, A.M., 2000. Measuring the thickness of the human cerebral cortex
from magnetic resonance images. PNAS 97, 11050e11055.
Fischl, B., Sereno, M.I., Dale, A.M., 1999. Cortical surface-based analysis: II: inﬂation,
ﬂattening, and a surface-based coordinate system. Neuroimage 9, 195e207.
Fjell, A.M., Westlye, L.T., Grydeland, H., Amlien, I., Espeseth, T., Reinvang, I., Raz, N.,
Dale, A.M., Walhovd, K.B. ADNI, 2014. Accelerating cortical thinning: unique to
dementia or universal in aging? Cereb. Cortex 24, 919e934.
Fortea, J., Sala-Llonch, R., Bartres-Faz, D., Bosch, B., Llado, A., Bargallo, N.,
Molinuevo, J.L., Sanchez-Valle, R., 2010. Increased cortical thickness and caudate
volume precede atrophy in PSEN1 mutation carriers. J. Alzheimers Dis. 22,
909e922.
Frangou, S., Aylward, E., Warren, A., Sharma, T., Barta, P., Pearlson, G., 1997. Small
planum temporale volume in Down’s syndrome: a volumetric MRI study. Am. J.
Psychiatry 154, 1424e1429.
Gili, T., Cercignani, M., Serra, L., Perri, R., Giove, F., Maraviglia, B., 2011. Regional brain
atrophy and functional disconnection across Alzheimer’s disease evolution.
J. Neurol. Neurosurg. Psychiatry 82, 58e66.
Gunn, R.N., Lammertsma, A.A., Hume, S.P., Cunningham, V.J., 1997. Parametric im-
aging of ligand-receptor binding in PET using a simpliﬁed reference region
model. Neuroimage 6, 279e287.
Handen, B.L., Cohen, A.D., Channamalappa, U., Bulova, P., Cannon, S.A., Cohen, W.I.,
Mathis, C.A., Price, J.C., Klunk, W.E., 2012. Imaging brain amyloid in non-
demented young adults with Down syndrome using Pittsburgh compound B.
Alzheimers Dement 8, 496e501.
Hartley, S.L., Handen, B.L., Devenny, D.A., Hardison, R., Mihaila, I., Price, J.C.,
Cohen, A.D., Klunk, W.E., Mailick, M.R., Johnson, S.C., Christian, B.T., 2014.
Cognitive functioning in relation to brain amyloid-beta in healthy adults with
Down syndrome. Brain 137, 2556e2563.
Jack, C.R., Lowe, V.J., Weigand, S.D., Wiste, H.J., Senjem, M.L., Knopman, D.S.,
Shiung, M.M., Gunter, J.L., Boeve, B.F., Kemp, B.J., Weiner, M., Petersen, R.C.,
2009. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s
disease: implications for sequence of pathological events in Alzheimer’s disease.
Brain 132, 1355e1365.
Jack, C.R., Twomey, C.K., Zinsmeister, A.R., Sharbrough, F.W., Petersen, R.C.,
Cascino, G.D., 1989. Anterior temporal lobes and hippocampal formations:
normative volumetric measurements from MR images in young adults. Radi-
ology 172, 549e554.
Kesslak, J.P., Nagata, S.F., Lott, I., Nalcioglu, O., 1994. Magnetic resonance imaging
analysis of age-related changes in the brains of individuals with Down’s syn-
drome. Neurology 44, 1039e1045.
Klunk, W.E., Price, J.C., Mathis, C.A., Tsopelas, N.D., Lopresti, B.J., Ziolko, S.K., Bi, W.,
Hoge, J.A., Cohen, A.D., Ikonomovic, M.D., Saxton, J.A., Snitz, B.E., Pollen, D.A.,
Moonis, M., Lippa, C.F., Swearer, J.M., Johnson, K.A., Rentz, D.M., Fischman, A.J.,
Aizenstein, H.J., DeKosky, S.T., 2007. Amyloid deposition begins in the striatum
of presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci. 27,
6174e6184.
Koivunen, J., Verkkoniemi, A., Aalto, S., Paetau, A., Ahonen, J.-P., Viitanen, M.,
Någren, K., Rokka, J., Haaparanta, M., Kalimo, H., Rinne, J.O., 2008. PET amyloid
ligand [11C]PIB uptake shows predominantly striatal increase in variant Alz-
heimer’s disease. Brain 131, 1845e1853.
Koran, M.E., Hohman, T.J., Edwards, C.M., Vega, J.N., Pryweller, J.R., Slosky, L.E.,
Crockett, G., Villa de Rey, L., Meda, S.A., Dankner, N., Avery, S.N., Blackford, J.U.,
Dykens, E.M., Thornton-Wells, T.A., 2014. Differences in age-related effects on
brain volume in Down syndrome as compared to Williams syndrome and
typical development. J. Neurodev Disord. 6, 8.
Krasuski, J.S., Alexander, G.E., Horwitz, B., Rapoport, S.I., Schapiro, M.B., 2002.
Relation of medial temporal lobe volumes to age and memory function in
nondemented adults with Down’s syndrome: implications for the prodromal
phase of Alzheimer’s disease. Am. J. Psychiatry 159, 74e81.
Landt, J., D’abrera, J.C., Holland, A.J., Aigbirhio, F.I., Fryer, T.D., Canales, R., Hong, Y.T.,
Menon, D.K., Baron, J.C., Zaman, S.H., 2011. Using positron emission tomography
and carbon 11-labeled Pittsburgh Compound B to image brain ﬁbrillar beta-
amyloid in adults with Down syndrome: safety, acceptability, and feasibility.
Arch. Neurol. 68, 890e896.
Lee, N.R., Adeyemi, E.I., Lin, A., Clasen, L.S., Lalonde, F.M., Condon, E., Driver, D.I.,
Shaw, P., Gogtay, N., Raznahan, A., Giedd, J.N., 2016. Dissociations in cortical
morphometry in youth with Down syndrome: evidence for reduced surface
area but increased thickness. Cereb. Cortex 26, 2982e2990.
Lott, I.T., Dierssen, M., 2010. Cognitive deﬁcits and associated neurological compli-
cations in individuals with Down’s syndrome. Lancet Neurol. 9, 623e633.
Mann, D.M.A., Esiri, M.M., 1989. The pattern of acquisition of plaques and tangles in
the brains of patients under 50 years of age with Down’s syndrome. J. Neurol.
Sci. 89, 169e179.
T. Annus et al. / Neurobiology of Aging 53 (2017) 11e19 19Mann, D.M.A., Jones, D., Prinja, D., Purkiss, M.S., 1990. The prevalence of
amyloid (A4) protein deposits within the cerebral and cerebellar cortex
in Down’s syndrome and Alzheimer’s disease. Acta Neuropathol. 80,
318e327.
Mann, D.M.A., Yates, P.O., Marcyniuk, B., 1984. Alzheimer’s presenile dementia,
senile dementia of Alzheimer’s type and Down’s syndrome in middle age form
an age related continuum of pathological changes. Neuropathol. Appl. Neuro-
biol. 10, 185e207.
Menghini, D., Costanzo, F., Vicari, S., 2011. Relationship between brain and cognitive
processes in Down syndrome. Behav. Genet. 41, 381e393.
Patenaude, B., Smith, S.M., Kennedy, D.N., Jenkinson, M., 2011. A Bayesian model of
shape and appearance for subcortical brain segmentation. Neuroimage 56,
907e922.
Pearlson, G.D., Breiter, S.N., Aylward, E.H., Warren, A.C., Grygorcewicz, M.,
Frangou, S., Barta, P.E., Pulsifer, M.B., 1998. MRI brain changes in subjects with
Down syndrome with and without dementia. Dev. Med. Child Neurol. 40,
326e334.
Pengas, G., Pereira, J.M.S., Williams, G.B., Nestor, P.J., 2009. Comparative reliability of
total intracranial volume estimation methods and the inﬂuence of atrophy in a
longitudinal semantic dementia cohort. J. Neuroimaging 19, 37e46.
Pievani, M., Bocchetta, M., Boccardi, M., Cavedo, E., Bonetti, M., Thompson, P.M.,
Frisoni, G.B., 2013. Striatal morphology in early-onset and late-onset Alz-
heimer’s disease: a preliminary study. Neurobiol. Aging 34, 1728e1739.
Pinter, J.D., Eliez, S., Schmitt, J.E., Capone, G.T., Reiss, A.L., 2001. Neuroanatomy of
Down’s syndrome: a high-resolution MRI study. Am. J. Psychiatry 158,
1659e1665.
Prasher, V., Cumella, S., Natarajan, K., Rolfe, E., Shah, S., Haque, M.S., 2003. Magnetic
resonance imaging, Down’s syndrome and Alzheimer’s disease: research and
clinical implications. JIDR 47, 90e100.
Raz, N., Torres, I.J., Briggs, S.D., Spencer, W.D., Thornton, A.E., Loken, W.J.,
Gunning, F.M., McQuain, J.D., Driesen, N.R., Acker, J.D., 1995. Selective neuro-
anatomic abnormalities in Down’s syndrome and their cognitive correlates:
evidence from MRI morphometry. Neurology 45, 356e366.
Remes, A.M., Laru, L., Tuominen, H., Aalto, S., Kemppainen, N., Mononen, H.,
Nagren, K., Parkkola, R., Rinne, J.O., 2008. Carbon 11-labeled pittsburghcompound B positron emission tomographic amyloid imaging in patients with
APP locus duplication. Arch. Neurol. 65, 540e544.
Rosas, H.D., Liu, A.K., Hersch, S., Glessner, M., Ferrante, R.J., Salat, D.H., van der
Kouwe, A., Jenkins, B.G., Dale, A.M., Fischl, B., 2002. Regional and progressive
thinning of the cortical ribbon in Huntington’s disease. Neurology 58, 695e701.
Roth, G.M., Sun, B., Greensite, F.S., Lott, I.T., Dietrich, R.B., 1996. Premature aging in
persons with Down syndrome: MR ﬁndings. Am. J. Neuroradiol 17, 1283e1289.
Schmidt-Sidor, B., Wisniewski, K.E., Shepard, T.H., Sersen, E.A., 1990. Brain growth in
Down syndrome subjects 15 to 22 weeks of gestational age and birth to 60
months. Clin. Neuropathol. 9, 181e190.
Smigielska-Kuzia, J., Bockowski, L., Sobaniec, W., Sendrowski, K., Olchowik, B.,
Cholewa, M., Lukasiewicz, A., Lebkowska, U., 2011. A volumetric magnetic
resonance imaging study of brain structures in children with Down syndrome.
Neurol. Neurochir Pol. 45, 363e369.
Teipel, S.J., Alexander, G.E., Schapiro,M.B.,Moller, H.J., Rapoport, S.I., Hampel,H., 2004.
Age-related cortical grey matter reductions in non-demented Down’s syndrome
adults determined by MRI with voxel-based morphometry. Brain 127, 811e824.
Teipel, S.J., Schapiro, M.B., Alexander, G.E., Krasuski, J.S., Horwitz, B., Hoehne, C.,
Moller, H.J., Rapoport, S.I., Hampel, H., 2003. Relation of corpus callosum and
hippocampal size to age in nondemented adults with Down’s syndrome. Am. J.
Psychiatry 160, 1870e1878.
Vandekar, S.N., Shinohara, R.T., Raznahan, A., Roalf, D.R., Ross, M., Deleo, N.,
Ruparel, K., Verma, R., Wolf, D.H., Gur, R.C., Gur, R.E., Satterthwaite, T.D., 2015.
Topologically dissociable patterns of development of the human cerebral cortex.
J. Neurosci. 35, 599e609.
Villemagne, V.L., Ataka, S., Mizuno, T., Brooks, W.S., Wada, Y., Kondo, M., Jones, G.,
Watanabe, Y., Mulligan, R., Nakagawa, M., Miki, T., Shimada, H., O’Keefe, G.J.,
Masters, C.L., Mori, H., Rowe, C.C., 2009. High striatal amyloid beta-peptide
deposition across different autosomal Alzheimer disease mutation types.
Arch. Neurol. 66, 1537e1544.
White, N.S., Alkire, M.T., Haier, R.J., 2003. A voxel-based morphometric study of
nondemented adults with Down Syndrome. Neuroimage 20, 393e403.
Wisniewski, K.E., 1990. Down syndrome children often have brain with maturation
delay, retardation of growth, and cortical dysgenesis. Am. J. Med. Genet. Suppl.
7, 274e281.
